Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

FDA Expands Approval for Novo Nordisk's Rybelsus, Setting New Benchmark for Oral Diabetes Medications

FDA Expands Approval for Novo Nordisk's Rybelsus, Setting New Benchmark for Oral Diabetes Medications

The U.S. Food and Drug Administration (FDA) has granted an expanded approval for Novo Nordisk's oral semaglutide treatment, Rybelsus, marking a significant advancement in the management of Type 2 diabetes and associated cardiovascular risks. This latest development positions Rybelsus as a pioneering oral medication in the GLP-1 therapy class, now recognized for its cardiovascular benefits.

NoahAI News10/22/2025
GSK's Oral Antibiotic Shows Promise in Phase 3 Trial for Complicated Urinary Tract Infections

GSK's Oral Antibiotic Shows Promise in Phase 3 Trial for Complicated Urinary Tract Infections

GSK and Spero Therapeutics have unveiled positive phase 3 results for their oral antibiotic candidate, tebipenem HBr, in the treatment of complicated urinary tract infections (cUTIs). The data, presented at ID Week 2025 in Atlanta, demonstrates that the oral therapy closely matched the efficacy of the intravenous standard of care, potentially paving the way for a new treatment option that could reduce hospital stays and healthcare costs.

NoahAI News10/22/2025
Novo Nordisk Foundation Overhauls Board Amid Obesity Market Challenges

Novo Nordisk Foundation Overhauls Board Amid Obesity Market Challenges

In a significant shake-up at one of the world's leading pharmaceutical companies, Novo Nordisk's largest investor has called for a dramatic restructuring of the company's board. This move comes as the Danish drugmaker grapples with shifting dynamics in the competitive obesity treatment market and recent large-scale layoffs.

NoahAI News10/22/2025
Electra Therapeutics Secures $183M Series C Funding for Rare Disease Treatment

Electra Therapeutics Secures $183M Series C Funding for Rare Disease Treatment

Electra Therapeutics, a South San Francisco-based biotech company, has successfully raised $183 million in a Series C financing round to advance its pivotal trial for a rare disease candidate. The oversubscribed funding, co-led by Nextech and EQT Life Sciences, marks a significant leap from the company's previous $84 million raise in 2022, signaling renewed investor confidence in the biotech sector.

NoahAI News10/22/2025
Regeneron Settles Eylea Patent Dispute with Celltrion, Paving Way for Biosimilar Launch

Regeneron Settles Eylea Patent Dispute with Celltrion, Paving Way for Biosimilar Launch

Regeneron Pharmaceuticals has reached a settlement agreement with South Korean drugmaker Celltrion, resolving their patent dispute over the blockbuster eye drug Eylea (aflibercept). This development marks a significant shift in the competitive landscape for age-related macular degeneration treatments, as it allows for the introduction of another biosimilar to the U.S. market.

NoahAI News10/22/2025
British Biotech Elevara Medicines Emerges with $70M Series A and Promising Rheumatoid Arthritis Asset

British Biotech Elevara Medicines Emerges with $70M Series A and Promising Rheumatoid Arthritis Asset

Elevara Medicines, a newly formed British biotech company, has burst onto the pharmaceutical scene with a substantial $70 million series A funding round and a phase 2-ready asset targeting rheumatoid arthritis (RA). The London-based firm, founded by Weatherden and initially backed by Monograph Capital, is poised to make waves in the treatment of chronic inflammatory conditions.

NoahAI News10/22/2025
FDA's Platform Technology Designation: Krystal Biotech Takes the Lead

FDA's Platform Technology Designation: Krystal Biotech Takes the Lead

In a significant development for the pharmaceutical industry, Krystal Biotech has become the recipient of the FDA's second-ever Platform Technology Designation (PTD) for its non-replicating HSV-1 viral vector. This designation, awarded on October 14, 2025, positions Krystal at the forefront of gene therapy innovation and potentially accelerates the development pathway for its pipeline products.

NoahAI News10/21/2025
Exelixis' Zanzalintinib Shows Promise in Late-Stage Colorectal Cancer Trial

Exelixis' Zanzalintinib Shows Promise in Late-Stage Colorectal Cancer Trial

Exelixis, a prominent player in the pharmaceutical industry, has unveiled promising results from its Phase III STELLAR-303 study, positioning its oral kinase inhibitor zanzalintinib as a potential new treatment option for patients with metastatic colorectal cancer (mCRC). The data, presented at the 2025 European Society for Medical Oncology (ESMO) meeting and simultaneously published in The Lancet, demonstrate significant improvements in overall survival rates, paving the way for a potential regulatory submission by year-end.

NoahAI News10/21/2025
Summit Therapeutics Pursues FDA Application for Ivonescimab Despite Mixed Clinical Results

Summit Therapeutics Pursues FDA Application for Ivonescimab Despite Mixed Clinical Results

Summit Therapeutics is moving forward with plans to submit a regulatory application for ivonescimab, its PD-1/VEGF inhibitor antibody, to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. This decision comes despite the drug's failure to meet overall survival (OS) endpoints in a recent Phase III trial for non-small cell lung cancer (NSCLC).

NoahAI News10/21/2025
Private Equity Firm Curewell Capital Invests in Wilmington PharmaTech to Boost US API Production

Private Equity Firm Curewell Capital Invests in Wilmington PharmaTech to Boost US API Production

Curewell Capital, a private equity firm focused on healthcare, has made a significant majority investment in Wilmington PharmaTech (WPT), a specialty contract development and manufacturing organization (CDMO). The move aims to address the lack of active pharmaceutical ingredient (API) infrastructure in the United States and expand domestic production capabilities.

NoahAI News10/21/2025
Galapagos to Wind Down Cell Therapy Unit, Impacting 365 Jobs and 5 Facilities

Galapagos to Wind Down Cell Therapy Unit, Impacting 365 Jobs and 5 Facilities

Belgian biotech company Galapagos has announced plans to wind down its cell therapy business, marking a significant shift in strategy that will affect hundreds of employees across multiple countries. The decision comes after a six-month period of uncertainty and failed attempts to find a suitable buyer for the unit.

NoahAI News10/21/2025
ACG Invests $200M in First US Empty-Capsule Facility, Expanding Global Footprint

ACG Invests $200M in First US Empty-Capsule Facility, Expanding Global Footprint

ACG, a leading supplier and service provider for solid dose drug manufacturers, has announced a significant investment of $200 million to establish its first empty-capsule production facility in the United States. This move marks a major expansion of the India-based company's global operations and strengthens its presence in the North American market.

NoahAI News10/21/2025
«1...141516...67»